Home
Current projects
Methods for valuing health states
Blog
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Direct to consumer genetic tests
Value of research
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Subscribe
Healthanomics
A collection of work and information about decision making in health
5 posts:
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
28.06.2008
Tagged as:
Paper
More details →
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
01.06.2008
Tagged as:
Paper
More details →
Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration
21.12.2007
Tagged as:
Paper
More details →
Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity
16.04.2007
Tagged as:
Paper
More details →
The Impact of Age-Related Macular Degeneration on Health Status Utility Values
01.11.2005
Tagged as:
Paper
More details →
Display multiple categories by selecting below
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Most important contributions
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis
Impact of the recall period on measuring health utilities for acute events
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
Using a discrete choice experiment to estimate societal health state utility values
Translator